Signal 3 availability limits the CD8 T cell response to a solid tumor

被引:46
作者
Curtsinger, Julie M. [1 ]
Gerner, Michael Y. [1 ]
Lins, Debra C. [1 ]
Mescher, Matthew F. [1 ]
机构
[1] Univ Minnesota, Ctr Immunol, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA
关键词
D O I
10.4049/jimmunol.178.11.6752
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
CD8 T cells need a third signal, along with Ag and costimulation, for effective survival and development of effector functions, and this can be provided by IL-12 or type I IFN. Adoptively transferred OT-I T cells, specific for H-2K(b) and OVA, encounter Ag in the draining lymph nodes of mice with the OVA-expressing E.G7 tumor growing at a s.c. site. The OT-I cells respond by undergoing limited clonal expansion and development of effector functions (granzyme B expression and IFN-gamma production), and they migrate to the tumor where they persist but fail to control tumor growth. In contrast, OT-I T cells deficient for both the IL-12 and type I IFN receptors expand only transiently and rapidly disappear. These results suggested that some signal 3 cytokine is available, but that it is insufficient to support a CTL response that can control tumor growth. Consistent with this, administration of IL-12 at day 10 of tumor growth resulted in a large and sustained expansion of wild-type OT-I cells with enhanced effector functions, and tumor growth was controlled. This did not occur when the OT-I cells lacked the IL-12 and type I IFN receptors, demonstrating that the therapeutic effect of IL-12 results from direct delivery of signal 3 to the CD8 T cells responding to tumor Ag in the signal 3-deficient environment of the tumor.
引用
收藏
页码:6752 / 6760
页数:9
相关论文
共 46 条
[1]   CD8+T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells [J].
Antony, PA ;
Piccirillo, CA ;
Akpinarli, A ;
Finkelstein, SE ;
Speiss, PJ ;
Surman, DR ;
Palmer, DC ;
Chan, CC ;
Klebanoff, CA ;
Overwijk, WW ;
Rosenberg, SA ;
Restifo, NP .
JOURNAL OF IMMUNOLOGY, 2005, 174 (05) :2591-2601
[2]   Sensitive and viable identification of antigen-specific CD8+T cells by a flow cytometric assay for degranulation [J].
Betts, MR ;
Brenchley, JM ;
Price, DA ;
De Rosa, SC ;
Douek, DC ;
Roederer, M ;
Koup, RA .
JOURNAL OF IMMUNOLOGICAL METHODS, 2003, 281 (1-2) :65-78
[3]   Antigen distribution drives programmed antitumor CD8 cell migration and determines its efficiency [J].
Boissonnas, A ;
Combadiere, C ;
Lavergne, E ;
Maho, M ;
Blanc, C ;
Debré, P ;
Combadiere, B .
JOURNAL OF IMMUNOLOGY, 2004, 173 (01) :222-229
[4]  
Curtsinger JM, 1999, J IMMUNOL, V162, P3256
[5]   Cutting edge: Type IIFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation [J].
Curtsinger, JM ;
Valenzuela, JO ;
Agarwal, P ;
Lins, D ;
Mescher, MF .
JOURNAL OF IMMUNOLOGY, 2005, 174 (08) :4465-4469
[6]   Signal 3 tolerant CD8 T cells degranulate in response to antigen but lack granzyme B to mediate cytolysis [J].
Curtsinger, JM ;
Lins, DC ;
Johnson, CM ;
Mescher, MF .
JOURNAL OF IMMUNOLOGY, 2005, 175 (07) :4392-4399
[7]   Signal 3 determines tolerance versus full activation of naive CD8 T cells: Dissociating proliferation and development of effector function [J].
Curtsinger, JM ;
Lins, DC ;
Mescher, MF .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (09) :1141-1151
[8]   Reversal of CD8+ T cell ignorance and induction of anti-tumor immunity by peptide-pulsed APC [J].
Dalyot-Herman, N ;
Bathe, OF ;
Malek, TR .
JOURNAL OF IMMUNOLOGY, 2000, 165 (12) :6731-6737
[9]  
Deeths MJ, 1999, EUR J IMMUNOL, V29, P45, DOI 10.1002/(SICI)1521-4141(199901)29:01<45::AID-IMMU45>3.0.CO
[10]  
2-I